Growth of 4.9% forecast for global B-cell NHL market to 2027
The B-cell non-Hodgkin’s lymphoma (NHL) market is expected to grow from $5.7 billion in 2017 to $9.2 billion by 2027 across the seven major markets (7MM: USA, France, Germany, Italy, Spain, UK and Japan) at a compound annual growth rate (CAGR) of 4.9%.
According to analytics firm GlobalData’s latest report: ‘ B-Cell Non-Hodgkin’s Lymphoma (NHL): Opportunity Analysis and Forecasts to 2027’, the main driver of the growth will be the rise of chimeric antigen receptor (CAR) T cell therapies.
CAR-T therapies, including the currently marketed Yescarta (axicabtagene ciloleucel) from Gilead Sciences (Nasdaq: GILD) and Kymriah (tisagenlecleucel) from Novartis (NOVN: VX) and the pipeline agent lisocabtagene maraleucel from Celgene (Nasdaq: CELG, are expected to result in significant revenues due to premium pricing and clinical benefit in heavily pre-treated patients. Their combined revenues are expected to reach around $2.4 billion in 2027.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze